ReviewCurrent oncology (Toronto, Ont.)2022
Lessons from Cost-Effectiveness Analysis of Smoking Cessation Programs for Cancer Patients.
Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Enhancing the long-term abstinence rate of smoking through telemedicine: A multicenter, retrospective cohort study in Japan.PloS one · 2026Article
- Assessment of Quality of Life in the Early Postoperative Period in Patients with Lung Cancer.International journal of environmental research and public health · 2025Article
- The impact of smoking on lung cancer patients.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Economic Considerations for Implementing Tobacco Cessation Programs in Cancer Care Settings.Cancer prevention research (Philadelphia, Pa.) · 2024Article
- Specialist cancer hospital-based smoking cessation service provision in Ireland.Irish journal of medical science · 2024Article
- Adolescent Tobacco/Nicotine Use and the Potential Role of Contingency Management-based Interventions.Journal of addiction medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmoking among patients diagnosed with cancer poses important health and financial challenges including reduced effectiveness of expensive cancer therapies. This study explores the value of smoking cessation programs (SCPs) for patients already diagnosed with cancer. It also identifies conditions under which SPCs may be wise investments.
methodsUsing a simplified decision analytic model combined with insights from a literature review, we explored the cost-effectiveness of SCPs.
resultsThe findings provide insights about the potential impact of cessation probabilities among cancer patients in SCPs and the potential impact of SCPs on cancer patients' lives.
conclusionThe evidence suggests that there is good reason to believe that SCPs are an economically attractive way to improve outcomes for cancer patients when SCPs are offered in conjunction with standard cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.